Manuscripts

Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.

Zhanel GG, Pozdirca M, Golden AR, Lawrence CK, Zelenitsky S, Berry L, Schweizer F, Bay D, Adam H, Zhanel MA, Lagacé-Wiens P, Walkty A, Irfan N, Naber K, Lynch JP 3rd, Karlowsky JA.

Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16.

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019.

Karlowsky JA, Walkty AJ, Baxter MR, Adam HJ, Lagacé-Wiens PRS, Schweizer F, Bay D, Lynch JP 3rd, Mulvey MR, Zhanel GG.

Microbiol Spectr. 2022 Aug 31;10(4):e0172422. doi: 10.1128/spectrum.01724-22. Epub 2022 Jun 27.

Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007-19.

Golden AR, Baxter MR, Karlowsky JA, Mataseje L, Mulvey MR, Walkty A, Bay D, Schweizer F, Lagace-Wiens PRS, Adam HJ, Zhanel GG.

JAC Antimicrob Resist. 2022 Feb 7;4(1):dlab197. doi: 10.1093/jacamr/dlab197. eCollection 2022 Mar.

Presence of the narrow-spectrum OXA-1 β-lactamase enzyme is associated with elevated piperacillin/tazobactam MIC values among ESBL-producing Escherichia coli clinical isolates (CANWARD, 2007-18).

Walkty A, Karlowsky JA, Lagacé-Wiens PRS, Golden AR, Baxter MR, Denisuik AJ, McCracken M, Mulvey MR, Adam HJ, Zhanel GG.

JAC Antimicrob Resist. 2022 Mar 21;4(2):dlac027. doi: 10.1093/jacamr/dlac027. eCollection 2022 Apr.

PCV-15 and PPSV-23 coverage of invasive and respiratory tract Streptococcus pneumoniae, including MDR and XDR isolates: CANWARD 2007-20.

Golden AR, Baxter M, Adam HJ, Martin I, Demczuk W, Mulvey MR, Karlowsky JA, Zhanel GG.

J Antimicrob Chemother. 2022 Apr 27;77(5):1444-1451. doi: 10.1093/jac/dkac034.

In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014-21).

Walkty AJ, Karlowsky JA, Baxter MR, Lagace-Wiens PRS, Adam HJ, Zhanel GG.

J Antimicrob Chemother. 2022 Nov 28;77(12):3414-3420. doi: 10.1093/jac/dkac333.

In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study.

Karlowsky JA, Baxter MR, Walkty AJ, Lagacé-Wiens PRS, Bay D, Adam HJ, Zhanel GG.

J Antimicrob Chemother. 2022 Oct 28;77(11):3035-3038. doi: 10.1093/jac/dkac275.

Antimicrobial resistance patterns of bacterial pathogens recovered from the urine of patients at Canadian hospitals from 2009 to 2020.

Walkty A, Karlowsky JA, Lagace-Wiens P, Baxter MR, Adam HJ, Zhanel GG.

JAC Antimicrob Resist. 2022 Nov 30;4(6):dlac122. doi: 10.1093/jacamr/dlac122. eCollection 2022 Dec.

Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.

Zhanel GG, Deng C, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, Berry L, Schweizer F, Zhanel MA, Irfan N, Bay D, Lagacé-Wiens P, Walkty A, Mandell L, Lynch JP 3rd, Karlowsky JA.

Drugs. 2021 Feb;81(2):233-256. doi: 10.1007/s40265-020-01443-4.

ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007-18.

Karlowsky JA, Walkty A, Golden AR, Baxter MR, Denisuik AJ, McCracken M, Mulvey MR, Adam HJ, Zhanel GG.

J Antimicrob Chemother. 2021 Oct 11;76(11):2815-2824. doi: 10.1093/jac/dkab269.

Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry.

Zhanel GG, Kosar J, Baxter M, Dhami R, Borgia S, Irfan N, MacDonald KS, Dow G, Lagacé-Wiens P, Dube M, Bergevin M, Tascini C, Keynan Y, Walkty A, Karlowsky J.

J Glob Antimicrob Resist. 2021 Mar;24:335-339. doi: 10.1016/j.jgar.2021.01.014. Epub 2021 Feb 1.

Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011-2018.

Golden AR, Fear T, Baxter M, Adam HJ, Martin I, Demczuk W, Karlowsky JA, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2021 Oct;101(2):115447. doi: 10.1016/j.diagmicrobio.2021.115447. Epub 2021 Jun 4.

In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019.

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Golden A, Lagace-Wiens P, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2021 Sep;101(1):115418. doi: 10.1016/j.diagmicrobio.2021.115418. Epub 2021 May 6.

Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.

Zhanel GG, Dhami R, Baxter M, Kosar J, Cervera C, Irfan N, Zvonar R, Borgia S, Tessier JF, Dow G, Ariano R, Dube M, Savoie M, Bassetti M, Walkty A, Karlowsky JA.

J Glob Antimicrob Resist. 2021 Jun;25:346-350. doi: 10.1016/j.jgar.2021.03.025. Epub 2021 May 11.

Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017.

Hink RK, Adam HJ, Golden AR, Baxter M, Martin I, Nichol KA, Demczuk W, Mulvey MR, Karlowsky JA, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2021 Mar;99(3):115282. doi: 10.1016/j.diagmicrobio.2020.115282. Epub 2020 Nov 27.

In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin.

Taylor RM, Karlowsky JA, Baxter MR, Adam HJ, Walkty A, Lagacé-Wiens P, Zhanel GG.

J Assoc Med Microbiol Infect Dis Can. 2021 Jul 20;6(2):149-162. doi: 10.3138/jammi-2020-0043. eCollection 2021 Jun.

Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018.

Golden AR, Adam HJ, Baxter M, Martin I, Demczuk W, Mulvey MR, Karlowsky JA, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Vaccine. 2021 Sep 15;39(39):5474-5483. doi: 10.1016/j.vaccine.2021.08.061. Epub 2021 Aug 25.

Use of Fosfomycin Etest To Determine In Vitro Susceptibility of Clinical Isolates of Enterobacterales Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci.

Karlowsky JA, Baxter MR, Golden AR, Adam HJ, Walkty A, Lagacé-Wiens PRS, Zhanel GG.

J Clin Microbiol. 2021 Nov 18;59(12):e0163521. doi: 10.1128/JCM.01635-21. Epub 2021 Sep 8.

In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007-18).

Zhanel GG, Adam HJ, Baxter M, Lagace-Wiens PRS, Karlowsky JA.

J Antimicrob Chemother. 2021 Jun 18;76(7):1808-1814. doi: 10.1093/jac/dkab098.

Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007-18.

Golden AR, Karlowsky JA, Walkty A, Baxter MR, Denisuik AJ, McCracken M, Mulvey MR, Adam HJ, Bay D, Zhanel GG.

J Antimicrob Chemother. 2021 Oct 11;76(11):2825-2832. doi: 10.1093/jac/dkab268.

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections.

Zhanel GG, Zhanel MA, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2020 Mar 28;2020:8513405. doi: 10.1155/2020/8513405. eCollection 2020.

Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.

Zhanel GG, Esquivel J, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, Hink R, Berry L, Schweizer F, Zhanel MA, Bay D, Lagacé-Wiens PRS, Walkty AJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2020 Feb;80(3):285-313. doi: 10.1007/s40265-020-01257-4.

In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.

Golden AR, Adam HJ, Baxter M, Walkty A, Lagacé-Wiens P, Karlowsky JA, Zhanel GG.

Diagn Microbiol Infect Dis. 2020 May;97(1):115012. doi: 10.1016/j.diagmicrobio.2020.115012. Epub 2020 Feb 4.

Fosfomycin resistance mediated by fos genes remains rare among extended-spectrum beta-lactamase-producing Escherichia coli clinical isolates recovered from the urine of patients evaluated at Canadian hospitals (CANWARD, 2007-2017).

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Alexander D, Bay DC, Boyd D, McCracken M, Mulvey MR, Zhanel GG.

Diagn Microbiol Infect Dis. 2020 Mar;96(3):114962. doi: 10.1016/j.diagmicrobio.2019.114962. Epub 2019 Dec 5.

Susceptibility of Clinical Isolates of Escherichia coli to Fosfomycin as Measured by Four In Vitro Testing Methods.

Karlowsky JA, Lagacé-Wiens PRS, Laing NM, Baxter MR, Adam HJ, Zhanel GG.

J Clin Microbiol. 2020 Sep 22;58(10):e01306-20. doi: 10.1128/JCM.01306-20. Print 2020 Sep 22.

Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017.

Karlowsky JA, Adam HJ, Baxter MR, Dutka CW, Nichol KA, Laing NM, Golding GR, Zhanel GG.

J Antimicrob Chemother. 2020 Jul 1;75(7):1824-1832. doi: 10.1093/jac/dkaa118.

Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16.

Lagacé-Wiens PRS, Adam HJ, Poutanen S, Baxter MR, Denisuik AJ, Golden AR, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Golding G, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD.

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv22-iv31. doi: 10.1093/jac/dkz284.

Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016.

Denisuik AJ, Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PRS, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD.

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv64-iv71. doi: 10.1093/jac/dkz289.

Characterization of MRSA in Canada from 2007 to 2016.

Nichol KA, Adam HJ, Golding GR, Lagacé-Wiens PRS, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD.

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv55-iv63. doi: 10.1093/jac/dkz288.

Species distribution and antifungal susceptibility of invasive Candida isolates from Canadian hospitals: results of the CANWARD 2011‑16 study.

Fuller J, Dingle TC, Bull A, Shokoples S, Laverdière M, Baxter MR, Adam HJ, Karlowsky JA, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD.

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv48-iv54. doi: 10.1093/jac/dkz287.

Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007‑16.

Golden AR, Baxter MR, Davidson RJ, Martin I, Demczuk W, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG, Adam HJ; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD.

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv39-iv47. doi: 10.1093/jac/dkz286.

Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007‑16 study.

McCracken MG, Adam HJ, Blondeau JM, Walkty AJ, Karlowsky JA, Hoban DJ, Zhanel GG, Mulvey MR; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD.

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv32-iv38. doi: 10.1093/jac/dkz285.

Ten years of the CANWARD Study (2007‑16).

Zhanel GG, Adam HJ; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD.

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv2-iv4. doi: 10.1093/jac/dkz282. No abstract available.

42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study.

Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Golden AR, Hink R, Lagacé-Wiens PRS, Walkty A, Mulvey MR, Schweizer F, Bay D, Hoban DJ, Karlowsky JA; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD.

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv5-iv21. doi: 10.1093/jac/dkz283.

Microbiology and Preclinical Review of Omadacycline.

Karlowsky JA, Steenbergen J, Zhanel GG.

Clin Infect Dis. 2019 Aug 1;69(Supplement_1):S6-S15. doi: 10.1093/cid/ciz395.

In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007‑2016.

Karlowsky JA, Lagacé-Wiens PRS, Adam HJ, Baxter MR, Laing NM, Walkty AJ, Zhanel GG.

Int J Antimicrob Agents. 2019 Jul;54(1):62-68. doi: 10.1016/j.ijantimicag.2019.04.012. Epub 2019 Apr 26.

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram‑Negative Bacilli.

Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.

Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Review.

Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013‑2017).

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Boyd D, Bharat A, Mulvey MR, Charles M, Bergevin M, Zhanel GG.

Diagn Microbiol Infect Dis. 2019 Jun;94(2):199-201. doi: 10.1016/j.diagmicrobio.2018.12.005. Epub 2018 Dec 14.

Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.

Denisuik AJ, Garbutt LA, Golden AR, Adam HJ, Baxter M, Nichol KA, Lagacé-Wiens P, Walkty AJ, Karlowsky JA, Hoban DJ, Mulvey MR, Zhanel GG.

J Antimicrob Chemother. 2019 Mar 1;74(3):645-653. doi: 10.1093/jac/dky477.

Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Review. Erratum in: Drugs. 2018 May 10. PMID: 29230684

In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.

Walkty A, Adam H, Baxter M, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2017 Dec 12. doi: 10.1093/jac/dkx468. [Epub ahead of print]. PMID: 29244121

In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015.

Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA.

Diagn Microbiol Infect Dis. 2018 May;91(1):55-62. doi: 10.1016/j.diagmicrobio.2017.12.013. Epub 2017 Dec 22. PMID: 29338931

PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2015.

Karlowsky JA, Walkty AJ, Baxter MR, Arhin FF, Moeck G, Adam HJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):105-111. doi: 10.1016/j.diagmicrobio.2018.01.017. Epub 2018 Jan 31. PMID: 29456070

Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli.

Zhanel GG, Zhanel MA, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2018 Jan 30;2018:1404813. doi: 10.1155/2018/1404813. eCollection 2018. Review. PMID: 29666664

Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 May;78(7):787. doi: 10.1007/s40265-018-0910-x. PMID: 29748749

Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-15.

Karlowsky JA, Adam HJ, Golden AR, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii5-vii11. doi: 10.1093/jac/dky156. PMID: 29982570

Introduction to the SAVE study (2011-15): Streptococcus pneumoniae serotyping and antimicrobial susceptibility: Assessment for Vaccine Efficacy in Canada after the introduction of PCV-13.

Zhanel GG, Adam HJ.

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii2-vii4. doi: 10.1093/jac/dky155. PMID: 29982571

Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15.

Adam HJ, Golden AR, Karlowsky JA, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii12-vii19. doi: 10.1093/jac/dky158. PMID: 29982572

Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-15.

Golden AR, Adam HJ, Karlowsky JA, Baxter M, Nichol KA, Martin I, Demczuk W, Van Caeseele P, Gubbay JB, Lefebvre B, Levett PN, Zahariadis G, Haldane D, Gad R, German G, Gilmour MW, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii20-vii31. doi: 10.1093/jac/dky157. PMID: 29982573

PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2015.

Lagacé-Wiens PRS, Adam HJ, Laing NM, Baxter MR, Martin I, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2017 Aug 1;72(8):2273-2277. doi: 10.1093/jac/dkx147. PMID: 28505331

Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model.

Zhanel GG, Parkinson K, Higgins S, Denisuik A, Adam H, Pitout J, Noreddin A, Karlowsky JA.

Diagn Microbiol Infect Dis. 2017 Jul;88(3):271-275. doi: 10.1016/j.diagmicrobio.2017.04.007. Epub 2017 Apr 23. PMID: 28483306

Antimicrobial susceptibility of 2906 Pseudomonas aeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015.

Walkty A, Lagace-Wiens P, Adam H, Baxter M, Karlowsky J, Mulvey MR, McCracken M, Zhanel GG.

Diagn Microbiol Infect Dis. 2017 Jan;87(1):60-63. doi: 10.1016/j.diagmicrobio.2016.10.003. Epub 2016 Oct 7. PMID: 28336136

In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.

Karlowsky JA, Walkty AJ, Baxter MR, Arhin FF, Moeck G, Adam HJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2017 Apr;87(4):349-356. doi: 10.1016/j.diagmicrobio.2017.01.006. Epub 2017 Jan 20. PMID: 28159446

Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015).

Walkty A, Karlowsky JA, Adam HJ, Lagacé-Wiens P, Baxter M, Mulvey MR, McCracken M, Poutanen SM, Roscoe D, Zhanel GG.

CMAJ Open. 2016 Oct 26;4(4):E641-E645. doi: 10.9778/cmajo.20160080. eCollection 2016 Oct-Dec. PMID: 28018876

Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.

Zhanel GG, Hartel E, Adam H, Zelenitsky S, Zhanel MA, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty AJ, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2016 Dec;76(18):1737-1757. Review. PMID: 27909995

Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis.

Zhanel GG, Walkty AJ, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2016;2016:2082693. doi: 10.1155/2016/2082693. Epub 2016 May 10. Review. PMID: 27366158

Invasive Streptococcus pneumoniae in Canada, 2011-2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F.

Golden AR, Adam HJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Vaccine. 2016 May 17;34(23):2527-30. doi: 10.1016/j.vaccine.2016.03.058. Epub 2016 Apr 13. PMID: 27085174

Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.

Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty A, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2016 Apr;76(5):567-88. doi: 10.1007/s40265-016-0545-8. Review. PMID: 26863149

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.

Zhanel GG, Walkty AJ, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2015 Nov-Dec;26(6):305-12. Review. PMID: 26744587

Telavancin: Mechanisms of Action, In Vitro Activity, and Mechanisms of Resistance.

Karlowsky JA, Nichol K, Zhanel GG.

Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S58-68. doi: 10.1093/cid/civ534. PMID: 26316559

Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13.

Golden AR, Rosenthal M, Fultz B, Nichol KA, Adam HJ, Gilmour MW, Baxter MR, Hoban DJ, Karlowsky JA, Zhanel GG.

J Antimicrob Chemother. 2015 Aug;70(8):2199-202. doi: 10.1093/jac/dkv107. Epub 2015 Apr 28. PMID: 25921512

Epidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007 to 2013).

Simner PJ, Adam H, Baxter M, McCracken M, Golding G, Karlowsky JA, Nichol K, Lagacé-Wiens P, Gilmour MW; Canadian Antimicrobial Resistance Alliance (CARA), Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2015 Jul;59(7):4315-7. doi: 10.1128/AAC.00384-15. Epub 2015 Apr 20. PMID: 25896693

In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible Gram-negative clinical isolates obtained from patients in Canadian hospitals.

Denisuik AJ, Karlowsky JA, Denisuik T, Nichols WW, Keating TA, Adam HJ, Baxter M, Walkty A,Zhanel GG.

Antimicrob Agents Chemother. 2015 Jun;59(6):3623-6. doi: 10.1128/AAC.00364-15. Epub 2015 Mar 30. PMID: 25824208

Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011-13.

Golden AR, Adam HJ, Gilmour MW, Baxter MR, Martin I, Nichol KA, Demczuk WH, Hoban DJ,Zhanel GG.

J Antimicrob Chemother. 2015 Jul;70(7):1960-4. doi: 10.1093/jac/dkv061. Epub 2015 Mar 11. PMID: 25761605

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, Gorityala B, Lagacé-Wiens PR, Rubinstein E, Walkty A, Gin AS, Gilmour M, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7. PMID: 25673021

In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.

Walkty A, Adam H, Baxter M, Denisuik A, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2014 May;58(5):2554-63. doi: 10.1128/AAC.02744-13. Epub 2014 Feb 18. PMID: 24550325

In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.

Karlowsky JA, Walkty AJ, Baxter MR, Adam HJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2014 Sep 16. pii: S0732-8893(14)00365-4. doi: 10.1016/j.diagmicrobio.2014.09.003. [Epub ahead of print] PMID: 25294303

Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.

Zhanel GG, Denisuik A, Vashisht S, Yachison C, Adam HJ, Hoban DJ.

J Antimicrob Chemother. 2014 Sep;69(9):2448-52. doi: 10.1093/jac/dku149. Epub 2014 May 14. PMID: 24827891

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2. PMID: 24352909

In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.

Karlowsky JA, Denisuik AJ, Lagacé-Wiens PR, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2014;58(2):1252-6. doi: 10.1128/AAC.02399-13. Epub 2013 Dec 9. PMID: 24323476

Introduction to the CANWARD study (2007–11).

Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i3-5. PMID: 23720829

Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study.

Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagacé-Wiens PR, Walkty A, Karlowsky JA, Schweizer F, Hoban DJ; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i7-22. PMID: 23587781 [PubMed - in process]

Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD).

Zelenitsky SA, Rubinstein E, Ariano RE, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i6-72. PMID: 23587780

Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.

Zelenitsky SA, Rubinstein E, Ariano RE, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i6-72. PMID: 23587779

Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada.

Nichol KA, Adam HJ, Roscoe DL, Golding GR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i47-55. PMID: 23587778

Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals.

Karlowsky JA, Adam HJ, Desjardins M, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i39-46. PMID: 23587777

Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult, and elderly patients in Canadian hospitals.

Adam HJ, Baxter MR, Davidson RJ, Rubinstein E, Fanella S, Karlowsky JA, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2013 May;68 Suppl 1:i31-7. PMID: 23587776

Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11.

Lagacé-Wiens PR, Adam HJ, Low DE, Blondeau JM, Baxter MR, Denisuik AJ, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i23-9. PMID: 23587775

Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2013 Feb;73(2):159-77. PMID: 23371303

Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011.

Walkty A, Baxter M, Adam H, Karlowsky JA, Lagacé-Wiens P, Hoban DJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2012 Aug;73(4):361-4. Epub 2012 Jun 12. PMID: 22694789

Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study.

Karlowsky JA, Walkty AJ, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2012 Mar;56(3):1247-52. Epub 2011 Dec 27. PMID: 22203594 [PubMed - indexed for MEDLINE]

Investigating the antimicrobial peptide 'window of activity' using cationic lipopeptides with hydrocarbon and fluorinated tails.

Findlay B, Zhanel GG, Schweizer F.

Int J Antimicrob Agents. 2012 Jul;40(1):36-42. PMID: 22578748

Oritavancin: mechanism of action.

Zhanel GG, Schweizer F, Karlowsky JA.

Clin Infect Dis. 2012 Apr;54 Suppl 3:S214-9. PMID: 22431851

Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.

Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA.

Expert Rev Anti Infect Ther. 2012 Apr;10(4):459-73. PMID: 22512755

Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.

Zhanel GG, Yachison C, Nichol K, Adam H, Noreddin AM, Hoban DJ, Karlowsky JA.

J Antimicrob Chemother. 2012 Jul;67(7):1706-11. PMID: 22467630

Baseline epidemiology of Streptococcus pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal vaccine.

Adam HJ, Karlowsky JA, Nichol KA, Gilmour MW, Hoban DJ, Embree J, Zhanel GG.

JMicrob Drug Resist. 2012 Apr;18(2):176-82. PMID: 22204595

Fluoroquinolone resistance in Escherichia coli isolated from patients attending Canadian hospitals is associated with the ST131 clone.

Simner PJ, Hoban DJ, Lagacé-Wiens PR, Zhanel GG, Karlowsky JA.

Diagn Microbiol Infect Dis. 2011 Nov;71(3):323-4. Epub 2011 Sep 1. No abstract available. PMID: 21889284 [PubMed - indexed for MEDLINE]

Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study.

Karlowsky JA, Lagacé-Wiens PR, Simner PJ, DeCorby MR, Adam HJ, Walkty A, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 Jul;55(7):3169-75. Epub 2011 May 2. PMID: 21537027[PubMed - indexed for MEDLINE]

In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).

Walkty A, DeCorby M, Lagacé-Wiens PR, Karlowsky JA, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 Jun;55(6):2992-4. Epub 2011 Mar 21. PMID: 21422208 [PubMed - indexed for MEDLINE]

Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

Lagacé-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 May;55(5):2434-7. Epub 2011 Feb 28. PMID: 21357295 [PubMed - indexed for MEDLINE]

In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.

Walkty A, Adam HJ, Laverdière M, Karlowsky JA, Hoban DJ, Zhanel GG; the Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):348-355. PMID: 21353964 [PubMed - as supplied by publisher]

In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.

Karlowsky JA, Adam HJ, Poutanen SM, Hoban DJ, Zhanel GG; The Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):342-347. PMID: 21353963 [PubMed - as supplied by publisher]

Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.

McCracken M, Mataseje LF, Loo V, Walkty A, Adam HJ, Hoban DJ, Zhanel GG, Mulvey MR; the Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):335-341. PMID: 21353962 [PubMed - as supplied by publisher]

Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study.

Simner PJ, Zhanel GG, Pitout J, Tailor F, McCracken M, Mulvey MR, Lagacé-Wiens PR, Adam HJ, Hoban DJ; the Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):326-334. PMID: 21353961[PubMed - as supplied by publisher]

Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study.

Nichol KA, Adam HJ, Hussain Z, Mulvey MR, McCracken M, Mataseje LF, Thompson K, Kost S, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; The Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):320-325. PMID: 21353960 [PubMed - as supplied by publisher]

Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada-results of the CANWARD 2007-2009 study.

Lagacé-Wiens PR, Simner PJ, Forward KR, Tailor F, Adam HJ, Decorby M, Karlowsky J, Hoban DJ, Zhanel GG; The Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):314-319. PMID: 21353959 [PubMed - as supplied by publisher]

Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study.

Adam HJ, Decorby M, Rennie R, Karlowsky JA, Hoban DJ, Zhanel GG; The Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):307-313. PMID: 21353958 [PubMed - as supplied by publisher]

Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study.

Zhanel GG, Adam HJ, Low DE, Blondeau J, Decorby M, Karlowsky JA, Weshnoweski B, Vashisht R, Wierzbowski A, Hoban DJ; The Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):291-306. PMID: 21353957 [PubMed - as supplied by publisher]

Introduction to the CANWARD Study (2007-2009).

Hoban DJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2011 Mar;69(3):289-90. No abstract available. PMID: 21353956 [PubMed - in process]

Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).

Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagacé-Wiens P, Nichol KA, Wierzbowski A, Baudry PJ, Tailor F, Karlowsky JA, Walkty A, Schweizer F, Johnson J; Canadian Antimicrobial Resistance Alliance, Hoban DJ.

ntimicrob Agents Chemother. 2010 Nov;54(11):4684-93. Epub 2010 Aug 30.PMID: 20805395 [PubMed - in process]

Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data.

Zelenitsky SA, Ariano RE, Zhanel GG.

J Antimicrob Chemother. 2010 Oct 5. [Epub ahead of print] PMID: 20926397 [PubMed - as supplied by publisher]

Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines.

Lynch JP 3rd, Zhanel GG.

Curr Opin Pulm Med. 2010 May;16(3):217-25.PMID: 20375783 [PubMed - in process]

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2010 May 7;70(7):859-86. doi: 10.2165/11534440-000000000-00000.PMID: 20426497 [PubMed - in process]